Sleep-Disordered Breathing and Coronary Artery Disease

Area of Science:

• Cardiology
• Sleep Medicine
• Pulmonology

Background:

• Coronary artery disease (CAD) remains a leading cause of mortality globally.
• Sleep-disordered breathing (SDB), characterized by intermittent hypoxia and sleep arousals, is increasingly recognized as a significant comorbidity.
• The vulnerable post-myocardial infarction (MI) heart may be particularly susceptible to the adverse effects of SDB.

Purpose of the Study:

• To investigate the association between SDB and outcomes in patients following acute myocardial infarction (MI).
• To evaluate the impact of SDB on myocardial ischemia, infarct size, and cardiac remodeling post-MI.
• To assess the feasibility of treating SDB in the early post-MI phase.

Main Methods:

• Observational study comparing patients with and without SDB after acute MI.
• Analysis of myocardial ischemia, salvaged myocardium, and left/right ventricular remodeling.
• Assessment of positive airway pressure (PAP) therapy for SDB suppression in the early post-MI period.

Main Results:

• Patients with SDB experienced prolonged myocardial ischemia and reduced salvaged myocardium despite successful percutaneous coronary intervention.
• SDB was associated with impaired left and right ventricular remodeling, increasing heart failure risk.
• Suppression of SDB with PAP therapy in the early post-MI phase was found to be feasible.

Conclusions:

• SDB is an independent risk factor associated with adverse outcomes in patients with acute MI.
• Untreated SDB exacerbates cardiac injury and remodeling post-MI, potentially leading to heart failure.
• Further research is needed to determine if SDB treatment can prevent heart failure development after MI.